Cholesterol absorption inhibitors (Formulary)

Important: Formulation and dosage details

Formulation:

Tablets 10mg

Dosage:

Ezetimibe may be considered in combination with a statin for patients who have failed to reach target cholesterol levels despite treatment with titrated/optimised statins alone. It may also be considered as monotherapy where statins are inappropriate or poorly tolerated. 

As per SMC 61/03: Ezetimibe may be considered in combination with a statin for patients who have failed to reach target cholesterol levels despite treatment with titrated/optimised statins alone.  It may also be considered as monotherapy where statins are inappropriate or poorly tolerated. 

Important: Formulation and dosage details

Formulation:

Tablets 180mg/10mg tablets (Nustendi®) (specialist initiation only)

Dosage:

See SMC 2406: : in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

• in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe,
• alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone
• in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin.

SMC restriction: for use in patients who are:

• statin intolerant or for whom a statin is contra-indicated and
• where ezetimibe alone does not appropriately control LDL-C and
• where proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors are not appropriate